| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
PULSAR [Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration] |
Total: 1011, into the following arms: 2q8, n = 337 8q12, n = 336 8q16, n = 338 |
Regeneron/Bayer NCT04423718 |
Primary completion: July 2022 Study completion: August 2024 |
N/A |
 [Lanzetta/ AAO 2022, p4] |